Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Market forces rained on the parade of Basilea Pharmaceutica AG ( VTX:BSLN ) shareholders today, when the analysts...
Swiss (SMI) Biotech Industry Analysis
UpdatedJul 01, 2022
DataAggregated Company Financials
Companies6
- 7D1.9%
- 3M-54.3%
- 1Y-73.0%
- YTD-51.4%
In the last week, the Biotech industry is up 3.0%, with Basilea Pharmaceutica up 7.5%. In the same time, Idorsia was down 5.1%. In the past year, the industry is down 74%. As for the next few years, earnings are forecast to decline by 70% per annum.
Industry Valuation and Performance
Has the Swiss Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Fri, 01 Jul 2022 | CHF545.5m | CHF454.2m | CHF80.7m | 2.2x |
| Sun, 29 May 2022 | CHF663.3m | CHF466.3m | CHF24.4m | 2.1x |
| Tue, 26 Apr 2022 | CHF983.0m | CHF295.7m | -CHF141,995,551.00 | 2x |
| Thu, 24 Mar 2022 | CHF1.2b | CHF285.2m | -CHF139,056,618.00 | 2x |
| Sat, 19 Feb 2022 | CHF1.3b | CHF281.7m | -CHF139,042,754.00 | 1.8x |
| Mon, 17 Jan 2022 | CHF5.1b | CHF315.7m | -CHF659,256,312.00 | 1.5x |
| Wed, 15 Dec 2021 | CHF3.8b | CHF318.6m | -CHF658,847,613.00 | 1.5x |
| Fri, 12 Nov 2021 | CHF4.1b | CHF317.8m | -CHF658,961,348.00 | 1.5x |
| Sun, 10 Oct 2021 | CHF4.9b | CHF287.4m | -CHF590,849,719.00 | 2.3x |
| Tue, 07 Sep 2021 | CHF5.2b | CHF305.7m | -CHF612,309,374.80 | 1.1x |
| Thu, 05 Aug 2021 | CHF5.4b | CHF306.0m | -CHF612,309,374.80 | 1.1x |
| Sun, 09 May 2021 | CHF5.5b | CHF352.3m | -CHF535,605,963.80 | 1.1x |
| Wed, 10 Feb 2021 | CHF7.0b | CHF407.2m | -CHF561,055,198.50 | 6.3x |
| Tue, 03 Nov 2020 | CHF6.2b | CHF399.6m | -CHF565,530,866.50 | 7.4x |
| Fri, 07 Aug 2020 | CHF4.3b | CHF393.6m | -CHF565,357,804.50 | 28.6x |
| Thu, 30 Apr 2020 | CHF835.1m | CHF327.2m | -CHF114,875,385.50 | 6.6x |
| Sun, 02 Feb 2020 | CHF5.0b | CHF460.8m | -CHF670,400,644.00 | n/a |
| Wed, 06 Nov 2019 | CHF3.6b | CHF473.1m | -CHF646,955,470.00 | n/a |
| Sat, 10 Aug 2019 | CHF3.4b | CHF449.1m | -CHF654,647,900.00 | n/a |
Median PE Ratio
n/a
Current Industry PE
- Investors are pessimistic on the industry, indicating that they anticipate long-term growth rates will be lower than they have historically.
- The industry is trading at a PE ratio of 6.7x which is higher than its 3-year average PE of -7.1x.
- The industry's 3-year average PS ratio 11.2x is higher than the industry's current PS ratio of 1.2x.
Past Earnings Growth
- Total earnings for the Biotechnology industry have gone up over the last three years, and the industry is now profitable.
- Revenues have remained mostly flat. This means that the industry has become more efficient since profits are increasing while sales have been flat.
Industry Comparison
How does Swiss Biotech compare with similar industries?
| CH Market | 2.45% | |
| Healthcare | 3.61% | |
| Biotech | 1.95% | |
| Biotech | 1.95% | |
Industry PEThere is insufficient data on the sub-industries of this industry.
Forecasted GrowthThere is insufficient data on the sub-industries of this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| BSLN Basilea Pharmaceutica | CHF38.60 | 7.5% +CHF32.0m | -13.3% | PS3.1x | |
| RLF Relief Therapeutics Holding | CHF0.033 | 15.8% +CHF18.5m | -83.0% | PS41.1x | |
| WBIO Wockhardt Bio | CHF1.58 | 17.0% +CHF11.9m | n/a | PE2.3x | |
| KURN Kuros Biosciences | CHF1.85 | 2.5% +CHF1.5m | -21.6% | PS4.4x |